EUVIMEDEUVIMED entdecken
Open Access

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia

Pamela Baker, Babajide Keshinro, Barbara Stegmann, Abbie Oey, Cathye Shu, Dirk Heerwegh, Rebecca Zaha, Hillary Van Valkenburgh

American Journal of Perinatology · 01.07.2026 · 43 (09) · 1256-1263

DOI: 10.1055/a-2761-1775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.07.2026. Verfasst von Pamela Baker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Spring House, Pennsylvania, United States. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Antibodies, Monoclonal, Humanized. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractThis article is a plain language summary of publication (PLSP) of the following articles: “Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-1)” by Tiller et al published in American Journal of Perinatology on July 28, 2025 (doi:10.1055/a-2666-5642) and “Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)” by Bussel et al published in American Journal of Perinatology on November 25, 2025 (doi: 10.1055/a-2753-9323). This PLSP describes the design of the phase 3, placebo-controlled FREESIA-1 and open-label FREESIA-3 trials, which will help researchers understand if nipocalimab, an investigational treatment, can be used to safely treat pregnant individuals who are at risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). This PLSP will help the general public, including those affected by FNAIT, and health care professionals understand the two studies. It provides information on the eligibility criteria, study design, treatments, and outcomes of interest. An infographic summary of this article is available in the Supplementary Material (available in the online version only).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocytopenia, Neonatal AlloimmuneAntibodies, Monoclonal, HumanizedHumansPregnancyFemaleClinical Trials, Phase III as TopicPlain Language SummariesRandomized Controlled Trials as TopicInfant, NewbornImmunoglobulins, IntravenousResearch DesignDouble-Blind Method

Substanzen

Antibodies, Monoclonal, HumanizedImmunoglobulins, Intravenousnipocalimab

Autor:innen und Institutionen

  • Johnson & Johnson, Spring House, Pennsylvania, United States.
  • Johnson & Johnson Biologics BV, Leiden, The Netherlands.
  • Johnson & Johnson, Beerse, Belgium.

Zitieren

APA

Baker, P., Keshinro, B., Stegmann, B., Oey, A., Shu, C., Heerwegh, D., Zaha, R., & Van Valkenburgh, H. (2026). Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology, 43(09), 1256-1263. https://doi.org/10.1055/a-2761-1775

Vancouver

Baker P, Keshinro B, Stegmann B, Oey A, Shu C, Heerwegh D, et al. Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology. 2026;43(09):1256-1263. doi:10.1055/a-2761-1775

BibTeX
@article{Baker2026,
  author = {Baker, Pamela and Keshinro, Babajide and Stegmann, Barbara and Oey, Abbie and Shu, Cathye and Heerwegh, Dirk and Zaha, Rebecca and Van Valkenburgh, Hillary},
  title = {Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia},
  journal = {American Journal of Perinatology},
  year = {2026},
  volume = {43},
  number = {09},
  pages = {1256--1263},
  doi = {10.1055/a-2761-1775}
}
Kostenlos starten →